TECH-MAHINDRA
7.12.2022 11:31:40 CET | Business Wire | Press release
Tech Mahindra, a leading provider of digital transformation, consulting, and business re-engineering services and solutions, today announced the launch of Cloud BlazeTech, an integrated, sector-agnostic platform, to maximize business value for cloud-powered enterprises globally. The organization will continue to invest in cloud services & hyperscaler relationships to boost digital transformation for enterprises.
Integrated cloud migration, cloud-native operation & self-healing governance model, "Cloud BlazeTech" supports bi-modal infrastructure transformation and helps enterprises to accelerate to a cloud-native world. In addition, the platform has integrations with hyperscaler hybrid cloud platforms to provide industry-specific pre-build cloud-native solutions that drive faster business outcomes. By adopting the Cloud BlazeTech platform, enterprises will achieve 25-30% cost savings and a 30% improvement in migration time.
Sudhir Nair, Chief Delivery Officer & Global Head – Infra & Cloud Business, Tech Mahindra, said, “Cloud adoption is a key step towards digital transformation. It is at the core of all transformative IT strategies and enables enterprises to become digital ready. Tech Mahindra’s Cloud BlazeTech platform will deliver industry-specific pre-build cloud-native solutions and help enterprises in their transformation journey to be cloud-ready. With this launch, we look forward to empowering every organization to be a digital organization, driving business outcomes, providing speed and scale to innovate from anywhere with cloud-based industry solutions, operation and governance, and innovation.”
Suri Chawla, Global Head of Cloud Services, Tech Mahindra, said, "In today's hyper-connected world, harnessing the power of the cloud has become a must-have element for businesses globally. In recent years, companies have realized the power of the cloud for business agility, innovation, improved customer experience, and the numerous opportunities cloud capabilities offer. To meet this growing need for Cloud tech and further our goal of providing best-in-class digital solutions, we have launched Cloud BlazeTech. Our platform will enable enterprises to move forward in their cloud transformation journey by offering a flexible and customizable solution to help them become digital front-runners in this new cloud-native era."
Tech Mahindra will leverage its existing partnerships with major public and private cloud service providers to extend its unique solution to global customers. Its dedicated cloud services, solutions, and framework has helped 250+ F100 & F500 customers in their cloud transformation journey, including some of the world's largest Cloud transformation projects for CME & enterprise verticals. Tech Mahindra will continue to invest in its cloud talent, build new solutions and focus on expanding relationships with all partners & hyperscalers.
For more information, please visit: https://www.techmahindra.com/en-in/infrastructure-and-cloud-services/cloud-blazetech/
Tech Mahindra believes in the DigitALL philosophy for comprehensive business transformation. Digital technologies catalyze the transformations – they humanize businesses by helping them think, sense, connect, communicate, secure and act better than before. As part of NXT.NOW™ framework, which aims to enhance the 'Human Centric Experience', Tech Mahindra focuses on investing in emerging technologies and solutions that enable digital transformation and meet the evolving needs of the customer.
Connect with us on www.techmahindra.com
Our Social Media Channels
Facebook: https://www.facebook.com/TechMahindra
Twitter: https://twitter.com/Tech_Mahindra
LinkedIn: https://www.linkedin.com/company/tech-mahindra/
YouTube: https://www.youtube.com/user/techmahindra09
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221207005389/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom